Association between IgM against an XXXX -modified peptide in apolipoprotein B-100 and progression of @entity66 .

@entity1 @entity1004 @entity1522 @entity66 @entity5470 @entity1406 @entity121 @entity264
BACKGROUND AND PURPOSE: Autoantibodies against antigens in oxidized low-density lipoprotein are common in @entity1 ; experimental studies suggest that these immune responses have a functional role in the disease process. The aim of this study was to evaluate the relationship between the immune response against one defined oxidized low-density lipoprotein antigen, the @entity264 -modified peptide corresponding @entity1522 3136 and 3155 (MDA-p210) in apolipoprotein (apo) B-100, and progression of carotid @entity121 ( @entity121 ). METHODS: IgM and IgG against MDA-p210 were determined by enzyme-linked immunosorbent assay at baseline and after 12 months of treatment with placebo, @entity1406 , @entity5470 , or @entity1406 / @entity5470 in 751 individuals participating in the BCAPS. Carotid @entity121 was assessed by ultrasonography at baseline and after 18 and 36 months of treatment. RESULTS: Antibody levels did not change in response to treatment, but high baseline MDA-p210 IgM levels were associated with a more rapid progression of @entity66 both at 18 (r=0.09, P<0.05) and 36 months (r=0.12, P<0.005). At 36 months, the difference in @entity121 progression rate per year between those with high MDA-p210 IgM levels and those with low was 0.011 mm (95% CI=0.005 to 0.018 mm, P<0.0001). Treatment with @entity5470 markedly decreased the progression of @entity121 among subjects with high but not with low MDA-p210 IgM levels. There was no association between MDA-p210 IgG and @entity1004 progression. CONCLUSIONS: IgM against the @entity264 -modified peptide corresponding @entity1522 3136 and 3155 in apo B-100 is common in subjects with asymptomatic @entity66 , and high levels are associated with a more rapid progression of @entity1004 . The observation that the effect of @entity5470 was restricted to subjects with high MDA-p210 IgM levels may reflect the increased rate of disease progression in this group.
